AFP and animal viral hepatitis: Thus, for surveillance of patients with chronic viral hepatitis and a specific risk profile like non-cirrhotic, steatotic HBV or HCV with SVR after DAA-treatment, ultrasound-based approaches and AFP alone are insufficient regarding sensitivity and should be complemented or even replaced by the GALAD measurement.